About 1AI
Algorae Pharmaceuticals develops three drug candidates — AI-116 for dementia, AI-168 for cardiovascular disease and NTCELL for Parkinson's — alongside an AI biopharmaceutical prediction platform.
All News for 1AI
No news articles found for 1AI yet.